Runway Growth Capital announced the closing of a senior secured term loan of $50 million to Gynesonics, a healthcare company focused on advancing women's health by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications.
 
Gynesonics has developed and has received FDA clearance for the Sonata® System, the world's first and only system that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation (RFA), offering a 100% incision-free, uterus preserving, outpatient procedure to treat a variety of different uterine fibroid types. This state-of-the-art technology provides women with a breakthrough alternative to hysterectomy or myomectomy (invasive surgical procedures), providing for a safe and effective uterus-preserving treatment.
 
"Gynesonics' approach to treating fibroids is game-changing in the women's healthcare space," says Rob Lake, Managing Director and Head of Life Sciences at Runway. "The current standard of care for treating symptomatic fibroids is far more invasive, requiring a myomectomy or in worst cases, a hysterectomy. Sonata's minimally invasive approach and intrauterine ultrasound capabilities have the potential to change how fibroids are treated and reshape how we approach intrauterine health."
 
"We've developed a long-standing and productive relationship with the Runway team that is built on trust and a keen understanding of the women's health space," said Chris Owens, President and CEO, Gynesonics. "Runway's strategic support will be vital to the full-scale global commercial launch of our intrauterine ultrasound technology in 2021 and beyond. Our Sonata procedure has been long sought out in the market, and with the support of Runway and our top tier investor group, we'll look to increase access to our disruptive technology and accelerate adoption."
 
"We are ecstatic to add Gynesonics to Runway's portfolio of innovative life sciences companies.This $50 million loan will provide a key resource to help Gynesonics to achieve its goals," Lake added.